MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...
MediWound Ltd.: MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...
MediWound begins pivotal Phase III trial for wound therapy
YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...
Science Daily2h
Decoding fat tissue
Research has uncovered key differences in gene expression linked to inflammation, metabolism and cardioprotection. These findings could help inform the development of targeted therapies for ...